FDA Draft Guidance Aims to Accelerate Cell and Gene Therapy Development
核心洞察
The FDA issued draft guidance to streamline regulatory submissions for gene therapies using genome editing in human somatic cells, leveraging platform knowledge and publicly available data.
Legend Biotech presented first-in-human data at ASCO 2026 showing its DLL3 (搜索)-targeted CAR-T therapy LB2102 demonstrated manageable safety and encouraging clinical activity in heavily pretreated solid tumor patients.
Laverock Therapeutics (搜索) secured approximately $2.8 million in grants to advance its AI-powered gene-control platform for T-cell and macrophage programs across oncology and non-oncology indications.
The US Food and Drug Administration has issued new draft guidance designed to help developers bring promising gene therapies to patients more efficiently. When finalized, the guidance will outline how sponsors can use publicly available information and established platform knowledge—including chemistry, manufacturing and controls (CMC) data, nonclinical study results, and clinical information—to streamline regulatory submissions for human gene therapy products that use genome editing in human somatic cells.
"Today's action reflects the FDA's commitment to get safe and effective cell and gene therapies to patients faster, particularly those living with rare and life-threatening diseases who have few or no other treatment options," said Karim Mikhail, Acting Director of the Center for Biologics Evaluation and Research. "By providing information on how companies may build on what is already known we are accelerating innovation without compromising the rigorous scientific standards that patients and the public depend on."
The guidance represents a significant regulatory development for the advanced therapies sector, where manufacturing complexity and lengthy development timelines have historically posed barriers to patient access.
Legend Biotech Reports Encouraging CAR-T Data at ASCO 2026
At the American Society of Clinical Oncology Annual Meeting held May 26 through June 2, 2026, Legend Biotech presented first-in-human clinical data for its DLL3 (搜索)-targeted CAR-T therapy, LB2102, in patients with relapsed or refractory small cell lung cancer (搜索) or large-cell neuroendocrine carcinoma (搜索). The therapy demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients.
"Patients with relapsed or refractory small cell lung cancer (搜索) or large-cell neuroendocrine carcinoma (搜索) have historically had very limited treatment options and poor outcomes," said Zhonglin Hao, Professor of Medicine and Cancer Biology and Director of the Thoracic Oncology Program at the University of Kentucky Markey Cancer Center. "Durable disease control and responses at higher dose levels with LB2102 are encouraging, particularly alongside a manageable safety profile. These findings support continued evaluation of CAR-T approaches in solid tumors, where effective therapies remain limited."
Legend Biotech also reported new analyses from the CARTITUDE program demonstrating continued sustained clinical benefits and a consistent safety profile of CARVYKTI in patients with multiple myeloma (搜索). Progression-free survival and overall survival benefits were observed across both high-risk and standard-risk cytogenetic populations among patients who responded to bridging therapy, with 30-month overall survival rates greater than 85%.
Laverock Therapeutics Secures $2.8 Million in Grant Funding
UK-based biotechnology company Laverock Therapeutics (搜索) has been awarded two new grants worth approximately $2.8 million to support the development of its gene-control platform. The platform spans a wide range of therapeutic applications and cell types, including developing programmed T cells and macrophages for solid tumor indications and hypoimmunogenic pancreatic islet cells for type 1 diabetes (搜索).
The first grant will scale the platform within T-cell products, utilizing solid tumor patient datasets and foundational data on intracellular signaling and antigen expression. Leveraging single-cell and AI-powered approaches, Laverock aims to rapidly identify preferred combinations of product features to unlock efficacy and safety in solid tumor cancer indications. The second grant will expand macrophage-based programs into non-oncology indications, building on the platform's ability to program myeloid cell phenotypes and precisely control therapeutic payload expression.
"Success in these two highly competitive grant competitions provides further validation of our approach and will enable us to expand our efforts across platform and product development," said David Venables, CEO of Laverock Therapeutics (搜索). "As we push towards the clinic for our lead program this additional funding will help unlock the true breadth of what our technology can achieve."